Results 31 to 40 of about 10,027 (205)

What has changed in thyroid eye disease in the last five years (2020–2025)

European Thyroid Journal
Background: Significant progress has been made in the management of thyroid eye disease (TED), based on the elucidation of important pathogenic mechanisms. This has led to novel therapeutics validated in randomized clinical trials.
Mario Salvi
doaj   +1 more source

Exploring thyroid eye disease in Brazil: insights from a single-center study [PDF]

Archives of Endocrinology and Metabolism
Objective: Graves’ disease (GD) is the leading cause of hyperthyroidism globally, with 40% of affected individuals developing thyroid eye disease (TED). Treatment options for TED have advanced in recent years.
Danilo Villagelin, Nicolas Perini, Roberto Bernardo Santos, João Hamilton Romaldini   +3 more
doaj   +1 more source

Case Reports of Teprotumumab as Treatment for Monoclonal Antibody-Induced Thyroid Orbitopathy

Reports
Background and Clinical Significance: Targeted biologic therapies, especially monoclonal antibodies (mAbs) such as nivolumab and alemtuzumab, have revolutionized treatment for malignancies and autoimmune conditions but can cause rare immune-related ...
Jared Moon, Nicole Duncan, Jeff Yorio, Ethan Meltzer, Moe H. Aung   +4 more
doaj   +1 more source

Identification and verification of the optimal feature genes of ferroptosis in thyroid-associated orbitopathy

Frontiers in Immunology
BackgroundThyroid-associated orbitopathy (TAO) is an autoimmune inflammatory disorder of the orbital adipose tissue, primarily causing oxidative stress injury and tissue remodeling in the orbital connective tissue.
Xuemei Li, Xuemei Li, Xuemei Li, Xuemei Li, Xuemei Li, Chao Xiong, Chao Xiong, Chao Xiong, Chao Xiong, Chao Xiong, Siyi Wang, Siyi Wang, Siyi Wang, Zhangjun Ren, Zhangjun Ren, Zhangjun Ren, Qi Jin, Qi Jin, Qi Jin, Jinhai Yu, Jinhai Yu, Jinhai Yu, Jinhai Yu, Jinhai Yu, Yunxiu Chen, Yunxiu Chen, Yunxiu Chen, Puying Gan, Puying Gan, Puying Gan, Puying Gan, Qihua Xu, Qihua Xu, Qihua Xu, Qihua Xu, Qihua Xu, Yaohua Wang, Yaohua Wang, Yaohua Wang, Yaohua Wang, Yaohua Wang, Hongfei Liao, Hongfei Liao, Hongfei Liao, Hongfei Liao, Hongfei Liao   +45 more
doaj   +1 more source

Exophthalmos in a young woman with no Graves’ disease – a case report of IgG4-related orbitopathy

BMC Ophthalmology, 2018
Background Immunoglobulin G4-related disease (IgG4-rd) is characterized by lymphoplasmacytic infiltration and tissue fibrosis. Orbital manifestations of IgG4-rd may include unilateral or bilateral proptosis, cicatricial extraocular muscle myopathy ...
Annamaria Erdei, Zita Steiber, Csaba Molnar, Ervin Berenyi, Endre V. Nagy   +4 more
doaj   +1 more source

The relation between clinical response and quality of life improvement after treatment with intravenous methylprednisolone in Graves' orbitopathy

Acta Ophthalmologica, EarlyView.
Abstract Background Quality of life (QoL) is a key outcome in Graves' orbitopathy (GO), but prior studies have reported overall QoL changes without evaluating whether improvements occur specifically in patients who achieve objective clinical response.
Gijsbert J. Hötte, Willem A. Dik, Ronald O. B. de Keizer, Sodaba Khatab, M. Medici, Sigrid M. A. Swagemakers, Peter J. van der Spek, P. Martin van Hagen, Dion Paridaens   +8 more
wiley   +1 more source

Diagnostic Options in Graves' or Non‐Graves' Thyrotoxicosis: A Review for Clinical Practice

Clinical Endocrinology, Volume 105, Issue 6, Page 603-609, December 2026.
ABSTRACT Objective Distinguishing Graves' disease (GD) from the other causes of thyrotoxicosis is essential for appropriate management. The clinical phenotype of GD has evolved over time and is currently more heterogenous and milder than in the past. Consequently, the differential diagnosis of thyrotoxicosis is often challenging.
Lorenzo Scappaticcio, Pierpaolo Trimboli, Paola Caruso, Chiara Porcellini, Daniela Forestiere, Maria Ida Maiorino, Katherine Esposito, Giuseppe Bellastella   +7 more
wiley   +1 more source

Efficacy of tocilizumab in resistant forms of Thyroid Eye Disease [PDF]

Medicinski Glasnik Specijalne Bolnice za Bolesti Štitaste Žlezde i Bolesti Metabolizma "Zlatibor"
Thyroid Eye Disease (TED), formerly known as Graves' orbitopathy, is an autoimmune disorder affecting orbital tissues. The Clinical Activity Score (CAS) is used to evaluate TED activity.
Marković Bojan, Joksimović Nata, Janić Tamara, Babić Jovana, Miletić Marija, Stojković Mirjana, Nedeljković-Beleslin Biljana, Ćirić Jasmina, Žarković Miloš   +8 more
doaj   +1 more source

Natural history of graves’ orbitopathy after treatment

, 2016
Intravenous glucocorticoids are used for Graves’ orbitopathy, alone or associated with/followed by additional treatments (orbital radiotherapy, orbital decompression, palpebral or eye surgery).
SELLARI FRANCESCHINI, STEFANO, MARINO', MICHELE, MENCONI, FRANCESCA, LEO, MARENZA, NARDI, MARCO, SABINI, ELENA, Sainato, Aldo, VITTI, PAOLO, MAUTONE, TERESA, MARCOCCI, CLAUDIO   +9 more
core   +1 more source

Single-cell transcriptomics in thyroid eye disease

Taiwan Journal of Ophthalmology
Thyroid eye disease (TED) is a poorly understood autoimmune condition affecting the retroorbital tissue. Tissue inflammation, expansion, and fibrosis can potentially lead to debilitating sequelae such as vision loss, painful eye movement, proptosis, and ...
Sofia Ahsanuddin, Albert Y. Wu
doaj   +1 more source